Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report highlights that the ISHRS website achieved 1,000,000 active users in 2025, signaling its emergence as a leading global resource for hair restoration information.

This study suggests that IGFBP-2 may play a role in basal cell carcinoma development by mediating epidermal progenitor cell expansion in hair follicles with activated Shh signaling.

This collection of abstracts from the 2025 IJCR Global Summit documents a diverse array of clinical research topics, with no new study results as they remain in their original submission format without peer review.

This article poses the question of whether Janus kinase (JAK) inhibitors are beneficial for treating androgenic alopecia, but it does not provide results or conclusions from any study.

This study found that KSR1 is essential for v-Ha-ras-mediated skin tumor formation in mice but not for MT-driven mammary tumor genesis, suggesting its potential as a therapeutic target in Ras/MAPK signaling.

This study found that combining Juniperus communis extract with 5-Fluorouracil inhibited oral cancer cell growth more effectively than 5-FU alone, inducing cancer cell death and reducing drug resistance by affecting key cellular pathways and proteins.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This study identified a novel CDH3 mutation associated with sparse hair and pigmentary macular changes in two siblings with hypotrichosis but no visual symptoms.

This study identified and characterized a murine type II hair keratin, demonstrating its presence in specific cells of hair and tongue tissues.

JAK inhibitors might help treat alopecia areata.

This supplement reviews advancements in the science of aging, including facial age simulation and stem cell applications for hair restoration, and reports no new clinical results.

This study identified a new mouse mutation associated with noninflammatory proliferative skin disease and hair abnormalities, drawing parallels to human conditions like Netherton's syndrome and monilethrix.

This study describes a new method using ImageJ to quantitatively assess hair loss in mice with alopecia areata, offering a more precise and reproducible alternative to traditional visual scoring systems by employing image-based analysis techniques.

This article reviews methods such as stem cell implantation to enhance hair transplant donor supply but reports no new clinical findings.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

In this study, mutations in the CDH3 gene were identified as the cause of hypotrichosis with juvenile macular dystrophy, and the researchers observed substantial phenotypic variability among affected individuals.

This study suggests that GATA6 is a key regulator of the upper pilo-sebaceous unit homeostasis and differentiation in human skin.

In this study, pediatric and young adults with alopecia areata reported high satisfaction with oral Janus kinase inhibitors, decreased hair loss severity, and a willingness to continue treatment despite potential risks, citing improvements in hair regrowth, tolerability, quality of life, and mental health.

This research discusses Stevens-Johnson syndrome and toxic epidermal necrolysis, life-threatening conditions often induced by immune-mediated drug reactions. Optimal management involves early diagnosis, drug withdrawal, and supportive therapy, though evidence for systemic treatments like corticosteroids and cyclosporin remains variable and lacks randomized controlled trial confirmation.

This study developed the iCOUNT tool, which provides insights into stem cell behavior by tracking cell division events and molecular consequences in human and mouse neural stem/progenitor cells.

Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.